SDZ GLC 756

Drug Profile

SDZ GLC 756

Alternative Names: GLC 756

Latest Information Update: 12 Oct 2005

Price : $50

At a glance

  • Originator Novartis
  • Class Antiglaucomas
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Glaucoma

Most Recent Events

  • 03 Oct 2000 Discontinued - Phase-I for Glaucoma in Switzerland (Ophthalmic)
  • 12 Jun 1997 New profile
  • 12 Jun 1997 Phase-I clinical trials for Glaucoma in Switzerland (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top